Compare Quest Diagnostics Inc (DGX) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ServiceNow Inc — how do they compare? Quest Diagnostics Inc trades at $203.96 (market cap $22.80B), while ServiceNow Inc trades at $104.79 (market cap $108.13B). The key difference: ServiceNow Inc is far larger — about 4.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals.
| DGX | NOW | |
|---|---|---|
Market Cap | $22.80B | $108.13B |
Sector | Health | Technology |
52-Week High | $216.02 | $199.24 |
52-Week Low | $166.42 | $83.00 |
Enterprise Value | $28.82B | $105.38B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
ServiceNow (NOW) trades at $111.26, up 3.3% on the day, with a bullish technical signal and strong fundamental growth. Revenue grew to $13.28B in 2025, with net income of $1.75B, though valuation ratios like P/E of 62.41 are elevated. Recent news highlights AI-driven growth opportunities, with the stock gaining 41% in May 2026 (Fool, 2026-06-03).
The outlook remains positive with an 85.51% analyst buy rating and a $137.41 consensus price target, implying significant upside. Risks include high valuation sensitivity and competitive pressures in enterprise AI. Cash flow trends show operational strength, but 2026 projections indicate potential net outflow, warranting monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
